The purchase of Livongo is the richest healthcare deal this year, but questions about reimbursement, competition and profitability remain.
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.
The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.
Livongo Health, which launched a highly successful IPO in July, claims to be one of the fastest-growing companies in Silicon Valley. Can it keep investors happy as growth…
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
The first quarter of this year saw more venture funding raised by medical device groups than any other period since 2010.